Clinical studies analyzing the expression of TIM-3, PD-1, and CTLA-4 on T cells after radiotherapy given to patients with prostate cancer have been conducted to evaluate changes in immune status after radiotherapy (NCT04624828). The gene discussed is HAVCR2; the disease is prostate cancer.